Authors
Yan-Chuan Shi
Publication date
2023/5/18
Journal
BIO Integration
Volume
4
Issue
1
Pages
3-6
Publisher
Compuscript
Description
“This commentary is written on the basis of a recent publication in Cell Metabolism by BIO Integration Editorial Board Member Dr. Sifan Chen and colleagues, entitled “Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.” Obesity and diabetes are major risk factors for severe SARS-CoV-2 infection, ICU admission and COVID-19-associated death [1]. Increasing evidence also suggests that SARS-CoV-2 infection disrupts glucose and lipid metabolism, promotes insulin resistance and endothelial dysfunction, and eventually may result in longterm metabolic defects and cardiovascular complications [2, 3]. However, the specific mechanisms through which SARS-CoV-2 infection drives these unfavorable metabolic events, and the optimal treatment strategies, remain elusive. After the SARS-CoV-2 virus enters the lungs, the viral …
Total citations